Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Integration of tumor-specific dendritic cell and antibody therapy within tumor drives innate and adaptive anti-cancer immunity [Metabolic_Pathways_NanoString]

ABSTRACT: Comparison of gene expression profiles of HER2+ murine mammary carcinoma treated with HER2 DC1, anti-Sema4D, and combination of both HER2 DC1 and anti-Sema4D therapy

ORGANISM(S): Mus musculus

PROVIDER: GSE302735 | GEO | 2026/02/02

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Integration of tumor-specific dendritic cell and antibody therapy within tumor drives innate and adaptive anti-cancer immunity [PanCancer_IO360_NanoString]

Project description:Comparison of gene expression profiles of HER2+ murine mammary carcinoma treated with HER2 DC1, anti-Sema4D, and combination of both HER2 DC1 and anti-Sema4D therapy

2026-02-02 | GSE302765 | GEO

Integration of tumor-specific dendritic cell and antibody therapy within tumor drives innate and adaptive anti-cancer immunity [Immunology_NanoString]

Project description:Comparison of gene expression profiles of HER2+ murine mammary carcinoma treated with HER2 DC1, anti-Sema4D, and combination of both HER2 DC1 and anti-Sema4D therapy

2026-02-02 | GSE302764 | GEO

Integration of tumor-specific dendritic cell and antibody therapy within tumor drives innate and adaptive anti-cancer immunity [Myeloid_Innate_Immunity_NanoString]

Project description:Comparison of gene expression profiles of HER2+ murine mammary carcinoma treated with HER2 DC1, anti-Sema4D, and combination of both HER2 DC1 and anti-Sema4D therapy

2026-02-02 | GSE302763 | GEO

Integration of tumor-specific dendritic cell and antibody therapy within tumor drives innate and adaptive anti-cancer immunity [Metabolic_Pathways_NanoString]

Project description:Integration of tumor-specific dendritic cell and antibody therapy within tumor drives innate and adaptive anti-cancer immunity [Metabolic_Pathways_NanoString]

| PRJNA1291818 | ENA

Integration of tumor-specific dendritic cell and antibody therapy within tumor drives innate and adaptive anti-cancer immunity [Myeloid_Innate_Immunity_NanoString]

Project description:Integration of tumor-specific dendritic cell and antibody therapy within tumor drives innate and adaptive anti-cancer immunity [Myeloid_Innate_Immunity_NanoString]

| PRJNA1292130 | ENA

Integration of tumor-specific dendritic cell and antibody therapy within tumor drives innate and adaptive anti-cancer immunity [Immunology_NanoString]

Project description:Integration of tumor-specific dendritic cell and antibody therapy within tumor drives innate and adaptive anti-cancer immunity [Immunology_NanoString]

| PRJNA1292133 | ENA

Integration of tumor-specific dendritic cell and antibody therapy within tumor drives innate and adaptive anti-cancer immunity [PanCancer_IO360_NanoString]

Project description:Integration of tumor-specific dendritic cell and antibody therapy within tumor drives innate and adaptive anti-cancer immunity [PanCancer_IO360_NanoString]

| PRJNA1292135 | ENA

Immune-stimulating antibody conjugates elicit robust myeloid activation and durable anti-tumor immunity I

Project description:Innate pattern recognition receptors, including toll-like receptors (TLRs), can alter the tumor microenvironment and prime adaptive anti-tumor immunity. However, TLR agonists have not been well-tolerated due to toxicities associated with widespreadimmune activation following systemic administration. To design a therapeutic that is suitable for systemic delivery and capable of eliciting a tumor-targeted response, we developed a novel class of immune-stimulating antibody conjugates (ISACs) comprising a TLR7/8 agonist conjugated to tumor-targeting antibodies. Systemically administered anti-HER2 ISACs were well-tolerated in vivo and elicited robust activation of intratumoral myeloid cells, resulting in tumor clearance and subsequent immunological memory. In vitro potency and in vivo efficacy required tandem activity driven by intact Fc functionality and TLR agonism to enable phagocytosis and T cell-mediated anti-tumor immunity. ISAC-mediated immunological memory was not limited to HER2, as ISAC-treated mice were protected from rechallenge with a HER2-negative tumor. These results provide strong rationale for the clinical development of ISACs and show that synergy between FcgR and TLR7/8 signaling contributes to the mechanism of ISAC-mediated anti-tumor immunity.

2020-12-03 | GSE157848 | GEO

Immune-stimulating antibody conjugates elicit robust myeloid activation and durable anti-tumor immunity II

Project description:Innate pattern recognition receptors, including toll-like receptors (TLRs), can alter the tumor microenvironment and prime adaptive anti-tumor immunity. However, TLR agonists have not been well-tolerated due to toxicities associated with widespread immune activation following systemic administration. To design a therapeutic that is suitable for systemic delivery and capable of eliciting a tumor-targeted response, we developed a novel class of immune-stimulating antibody conjugates (ISACs) comprising a TLR7/8 agonist conjugated to tumor-targeting antibodies. Systemically administered anti-HER2 ISACs were well-tolerated in vivo and elicited robust activation of intratumoral myeloid cells, resulting in tumor clearance and subsequent immunological memory. In vitro potency and in vivo efficacy required tandem activity driven by intact Fc functionality and TLR agonism to enable phagocytosis and T cell-mediated anti-tumor immunity. ISAC-mediated immunological memory was not limited to HER2, as ISAC-treated mice were protected from rechallenge with a HER2-negative tumor. These results provide strong rationale for the clinical development of ISACs and show that synergy between FcgR and TLR7/8 signaling contributes to the mechanism of ISAC-mediated anti-tumor immunity.

2020-12-03 | GSE157869 | GEO

Identification of resistance mechanisms to anti-HER2 antibody in breast cancer cell line BT-474

Project description:Background: The addition of the anti-HER2 antibody pertuzumab to trastuzumab/chemotherapy treatment in HER2+ breast cancer significantly improves clinical outcome. Concomitantly, the drug-antibody conjugate T-DM1 (trastuzumab-emantasine) has demonstrated efficacy, at least equal, to the combination of trastuzumab/chemotherapy. Scientific, economic and health challenges emerge from the clinical use of these novel anti-HER2 antibodies, aimed to identify new resistance mechanisms and to select the target breast cancer population. Objectives: (1) To identify primary resistance mechanisms to anti-HER2 antibodies trastuzumab, pertuzumab, and to the combined trastuzumab/pertuzumab or pertuzumab/T-DM1 therapy, (2) To identify acquired resistance mechanisms to anti-HER2 antibodies trastuzumab, pertuzumab, and to the combined trastuzumab/pertuzumab or pertuzumab/T-DM1 therapy, (3) To develop new combinations of anti-HER2 antibodies with other targeted therapies.

2019-12-31 | GSE89216 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data